Results 181 to 190 of about 212,546 (262)
A mitochondrial-based prognostic score for risk stratification in acute myeloid leukemia. [PDF]
Santos IC +10 more
europepmc +1 more source
Senotherapeutics for Knee Osteoarthritis
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman +6 more
wiley +1 more source
Apoptosis-related gene model predicts the prognosis in patients with acute myeloid leukemia. [PDF]
Pei X +5 more
europepmc +1 more source
Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli +5 more
wiley +1 more source
Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia? [PDF]
Alati C +11 more
europepmc +1 more source
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean +3 more
wiley +1 more source
Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia. [PDF]
Chiusolo P +10 more
europepmc +1 more source
Information Design for Early‐Stage Dose‐Finding Trials
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley +1 more source

